SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
Author:
Publisher
Elsevier BV
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference11 articles.
1. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018;Diabetes Care,2018
2. The cardiovascular biology of glucagon-like peptide-1;Drucker;Cell Metab,2016
3. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications;Heerspink;Circulation,2016
4. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes;Muskiet;Nat Rev Nephrol,2017
5. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum;Cefalu;Diabetes Care,2018
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus;Acta Diabetologica;2023-06-04
2. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review;Expert Review of Endocrinology & Metabolism;2023-05-08
3. AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.;2022-12-28
4. AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.;2022-10-11
5. Biochemical Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population;Journal of Cardiovascular Pharmacology;2022-05-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3